Equities
  • Price (EUR)3.15
  • Today's Change-0.01 / -0.32%
  • Shares traded99.59k
  • 1 Year change+0.48%
  • Beta0.5639
Data delayed at least 15 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.

  • Revenue in EUR (TTM)451.17m
  • Net income in EUR91.90m
  • Incorporated--
  • Employees1.75k
  • Location
    Faes Farma SAEdificio 2, 2 IzquierdaMADRID 28033SpainESP
  • Phone+34 914680800
  • Fax+34 944818201
  • Websitehttps://faesfarma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Surgical Science Sweden AB76.84m20.36m676.83m260.0033.211.7926.858.814.594.5917.3285.160.18881.876.153,395,589.005.004.495.314.7869.4270.0626.5023.753.56----0.0010.0168.1424.47--38.57--
Pharming Group N.V.226.60m-9.35m677.36m390.00--3.34126.302.99-0.0139-0.01390.33580.30250.5530.50896.65---2.285.28-2.696.6689.7289.41-4.129.303.41-0.81310.439--19.309.01-174.00---13.04--
Puretech Health PLC10.84m-43.43m709.06m111.00--1.60--65.40-0.1316-0.13160.03281.410.0155--3.6383,673.96-5.165.21-5.906.53-----333.47265.77---34.790.04790.00-10.1843.8616.85--0.046--
Eckert & Ziegler SE246.09m30.01m788.02m1.08k25.853.4917.973.201.441.2611.8110.670.58123.285.63228,923.707.208.508.6710.2347.2948.6112.3914.002.3112.770.200835.0910.747.84-2.8413.2233.82-30.12
Formycon AG68.64m-42.24m818.40m224.00--1.74--11.92-2.80-2.804.4126.650.07991.542.24334,839.00-4.863.03-5.173.2935.5231.61-61.5310.911.00--0.02020.0016.077.86370.82--120.72--
Abivax SA0.00-92.25m835.39m26.00--7.02-----2.89-2.890.001.890.00----0.00-76.01-55.61-113.62-81.62-----------5.090.3602-------68.89--32.30--
Swedencare AB (publ)203.53m5.10m898.00m560.00176.071.4328.014.410.36920.369214.7345.400.23952.5010.234,175,714.000.60021.380.61951.4355.2055.342.515.101.991.960.187145.3327.4888.16-37.9620.2430.90--
EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr124.60m106.82m994.88m1.12k9.311.878.627.985.455.456.3627.090.25643.437.133,764,577.0021.9815.3624.3716.3043.4634.5885.74113.931.24--0.1317--65.8925.08230.6397.4282.99--
FAES Farma SA451.17m91.90m997.69m1.75k10.661.488.982.210.29590.29591.452.130.60091.263.96258,105.3012.2113.0713.9115.2065.8664.1020.3219.791.86--0.0348--2.836.832.6312.2439.26--
Polypeptide Group AG324.79m-51.43m1.00bn1.20k--2.61--3.08-1.52-1.529.5911.310.51372.315.08264,408.70-8.132.59-10.373.262.8123.73-15.834.581.12-1.560.246615.7914.6012.36-762.29--25.40--
AddLife AB842.95m16.62m1.12bn2.31k69.732.6911.491.331.571.5779.4840.690.75073.696.19--1.495.312.258.8337.1636.671.985.790.45411.810.51631.736.6231.30-60.428.0042.31-1.89
BioGaia AB112.84m31.80m1.13bn213.0036.986.6533.3210.043.623.6212.8420.110.5703------16.0715.4717.4516.9373.2973.3028.1827.70------104.4217.4411.81-2.2511.2029.3528.10
Vetoquinol SA525.26m58.83m1.19bn2.52k20.092.3413.192.264.974.9744.4042.730.82432.145.35208,353.009.236.9511.549.2150.6661.2611.208.631.70--0.030316.183.558.92-23.656.6210.4211.70
Cosmo Pharmaceuticals NV96.70m1.15m1.25bn325.001,003.192.6980.3012.960.06970.06975.8726.010.14733.062.88291,165.400.20510.24370.2490.26759.3357.281.392.103.802.730.0042841.86-5.268.07-93.34--9.62--
Bonesupport Holding AB51.45m21.33m1.28bn110.0060.7327.4458.2424.873.723.729.048.241.110.71866.605,373,428.0046.20-9.0858.31-11.2891.5190.2541.45-11.652.46--0.0311--79.7643.65459.44--18.39--
Fagron NV762.99m70.55m1.28bn3.46k18.142.7611.891.680.96640.966410.456.350.77153.8712.43220,517.607.187.638.769.7743.5943.499.3110.231.274.450.439516.2811.5710.101.3410.4819.6420.11
Data as of Mar 28 2024. Currency figures normalised to Faes Farma SA's reporting currency: Euro EUR

Institutional shareholders

15.96%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 07 Mar 202411.12m3.52%
Alantra EQMC Asset Management SGIIC SAas of 04 Dec 20239.53m3.02%
Norges Bank Investment Managementas of 10 Nov 20229.28m2.93%
BlackRock Fund Advisorsas of 07 Mar 20244.75m1.50%
Dimensional Fund Advisors LPas of 07 Mar 20244.66m1.47%
Fidelity Management & Research Co. LLCas of 31 Dec 20233.47m1.10%
Argenta Spaarbank NVas of 30 Jun 20232.14m0.68%
Santander Asset Management SA SGIICas of 31 Dec 20232.10m0.66%
KBC Asset Management NVas of 30 Jun 20231.77m0.56%
Serafin Asset Management AGas of 30 Jun 20231.67m0.53%
More ▼
Data from 30 Nov 2023 - 13 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.